Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to invest in the U.S. as tariffs targeting the industry loom. The facility’s products will include biologic drugs and a new,

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in Ireland and Singapore, in addition to its arrangements with contract manufacturers. Last year, Keytruda generated sales of $29.5 billion, accounting for 46% of the company’s revenue of $64.2 billion.